norstella-logo-white
News

How Norstella is embedding artificial intelligence to improve pipeline to patient decision-making

By Daniel Chancellor

VP Thought Leadership | Norstella

As drug discovery becomes more complex, expensive, and challenging, it is imperative for companies to innovate to stay ahead. Scientific advancements and the latest drug technologies are an important response, but artificial intelligence is poised to revolutionize the decision making at the heart of R&D (in)efficiency.

Norstella and its constituent brands – Citeline, Evaluate, MMIT, The Dedham Group, and Panalgo – each have a long history in providing the data and products that underpin biopharma strategies. Biopharmaceutical companies rely on us for decisions from designing clinical trials to mitigating portfolio risk, launching new drugs and understanding payer dynamics.

In this white paper, Norstella describes its vision for the integration of artificial intelligence with its industry-leading data and advisory services. At each step from pipeline to patient, Norstella is embedding AI to create the next generation of solutions. These will help biopharma professionals to better contextualize their challenges, predict how scenarios will play out, as well as guiding decisions for the optimal outcome. The first tools are already available to the market, and development continues at pace.

Download the ebook to learn more about Norstella’s latest AI product development: How Norstella is embedding artificial intelligence to improve pipeline to patient decision-making

 

Description of Image

Work with us

Join our mission

We’re looking for agile, growth-oriented team players who are passionate about client success and helping clients bring life-saving therapies to market quicker—and help patients in need.

Work with us

Get in Touch

Let's connect

Have questions about Norstella or its brands? Or do you want to know more about how to solve your challenges at each stage of the drug life cycle?

We want to hear from you